{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T11:27:30Z","timestamp":1794569250077,"version":"4.9.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100013301","name":"Parkinson's Foundation","doi-asserted-by":"publisher","award":["PF-PRF-934916"],"award-info":[{"award-number":["PF-PRF-934916"]}],"id":[{"id":"10.13039\/100013301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["860197"],"award-info":[{"award-number":["860197"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["860197"],"award-info":[{"award-number":["860197"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-54878-8","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T01:56:07Z","timestamp":1735869367000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Immunoassay detection of multiphosphorylated tau proteoforms as cerebrospinal fluid and plasma Alzheimer\u2019s disease biomarkers"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6958-8223","authenticated-orcid":false,"given":"Anna L.","family":"Wojda\u0142a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0456-5650","authenticated-orcid":false,"given":"Giovanni","family":"Bellomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3967-8954","authenticated-orcid":false,"given":"Lorenzo","family":"Gaetani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4061-0837","authenticated-orcid":false,"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5722-3967","authenticated-orcid":false,"given":"Lucilla","family":"Parnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1169-3258","authenticated-orcid":false,"given":"Davide","family":"Chiasserini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"54878_CR1","doi-asserted-by":"crossref","unstructured":"2023 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 19, 1598\u20131695 (2023).","DOI":"10.1002\/alz.13016"},{"key":"54878_CR2","doi-asserted-by":"publisher","unstructured":"2020 Alzheimer\u2019s disease facts and figures. Alzheimers Dement https:\/\/doi.org\/10.1002\/alz.12068 (2020).","DOI":"10.1002\/alz.12068"},{"key":"54878_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med"},{"key":"54878_CR4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","volume":"20","author":"L S\u00f6derberg","year":"2023","unstructured":"S\u00f6derberg, L. et al. Lecanemab, aducanumab, and gantenerumab - binding profiles to different forms of amyloid-beta might explain efficacy and side effects in clinical trials for Alzheimer\u2019s Disease. Neurotherapeutics 20, 195\u2013206 (2023).","journal-title":"Neurotherapeutics"},{"key":"54878_CR5","doi-asserted-by":"crossref","unstructured":"J\u00f6nsson, L. et al. Viewpoint The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer\u2019 s disease: an EADC-EC viewpoint. 29, 1\u20137 (2023).","DOI":"10.1016\/j.lanepe.2023.100657"},{"key":"54878_CR6","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.3233\/JAD-170773","volume":"62","author":"K Blennow","year":"2018","unstructured":"Blennow, K. & Zetterberg, H. The past and the future of Alzheimer\u2019s disease fluid biomarkers. J. Alzheimer\u2019s. Dis. 62, 1125\u20131140 (2018).","journal-title":"J. Alzheimer\u2019s. Dis."},{"key":"54878_CR7","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13024-022-00586-0","volume":"17","author":"J Gobom","year":"2022","unstructured":"Gobom, J. et al. Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer\u2019s disease continuum. Mol. Neurodegener. 17, 81 (2022).","journal-title":"Mol. Neurodegener."},{"key":"54878_CR8","doi-asserted-by":"crossref","unstructured":"Ashton, N. J. et al. Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer\u2019s disease. eBioMedicine 76, 103836 (2022).","DOI":"10.1016\/j.ebiom.2022.103836"},{"key":"54878_CR9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s43587-023-00380-7","volume":"3","author":"NR Barth\u00e9lemy","year":"2023","unstructured":"Barth\u00e9lemy, N. R. et al. CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer\u2019s disease. Nat. Aging 3, 391\u2013401 (2023).","journal-title":"Nat. Aging"},{"key":"54878_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-15436-0","volume":"11","author":"S Janelidze","year":"2020","unstructured":"Janelidze, S. et al. Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer\u2019s disease. Nat. Commun. 11, 1\u201312 (2020).","journal-title":"Nat. Commun."},{"key":"54878_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46876-7","volume":"15","author":"PR Kac","year":"2024","unstructured":"Kac, P. R. et al. Plasma p-tau212 antemortem diagnostic performance and prediction of autopsy verification of Alzheimer\u2019s disease neuropathology. Nat. Commun. 15, 2615 (2024).","journal-title":"Nat. Commun."},{"key":"54878_CR12","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen, E. H. et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat. Med. 26, 387\u2013397 (2020).","journal-title":"Nat. Med."},{"key":"54878_CR13","first-page":"1797","volume":"28","author":"M Mil\u00e0-Alom\u00e0","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0, M. et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat. Med. 28, 1797\u20131801 (2022).","journal-title":"Nat. Med."},{"key":"54878_CR14","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze, S. et al. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat. Med. 26, 379\u2013386 (2020).","journal-title":"Nat. Med."},{"key":"54878_CR15","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer's disease vs other neurodegenerative disorders. JAMA 324, 772 (2020).","journal-title":"JAMA"},{"key":"54878_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem.20200861","volume":"217","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy, N. R., Horie, K., Sato, C. & Bateman, R. J. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease. J. Exp. Med. 217, 1\u201312 (2020).","journal-title":"J. Exp. Med."},{"key":"54878_CR17","doi-asserted-by":"crossref","unstructured":"Wilson, E. N. et al. Performance of a fully\u2014automated Lumipulse plasma phospho \u2011 tau181 assay for Alzheimer\u2019 s disease. Alzheimer\u2019s Res. Ther. 14, 172 (2022).","DOI":"10.1186\/s13195-022-01116-2"},{"key":"54878_CR18","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton, N. J. et al. Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathologica 141, 709\u2013724 (2021).","journal-title":"Acta Neuropathologica"},{"key":"54878_CR19","doi-asserted-by":"publisher","unstructured":"Brickman, A. M. et al. Plasma p-tau181, p-tau217, and other blood-based Alzheimer\u2019s disease biomarkers in a multi-ethnic, community study. 1353\u20131364 https:\/\/doi.org\/10.1002\/alz.12301 (2021).","DOI":"10.1002\/alz.12301"},{"key":"54878_CR20","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s43587-023-00405-1","volume":"3","author":"L Montoliu-Gaya","year":"2023","unstructured":"Montoliu-Gaya, L. et al. Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies. Nat. Aging 3, 661\u2013669 (2023).","journal-title":"Nat. Aging"},{"key":"54878_CR21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00401-020-02195-x","volume":"140","author":"J Lantero Rodriguez","year":"2020","unstructured":"Lantero Rodriguez, J. et al. Plasma p-tau181 accurately predicts Alzheimer\u2019s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol. 140, 267\u2013278 (2020).","journal-title":"Acta Neuropathol."},{"key":"54878_CR22","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen, E. H. et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol. 20, 739\u2013752 (2021).","journal-title":"Lancet Neurol."},{"key":"54878_CR23","doi-asserted-by":"crossref","unstructured":"Gonzalez-Ortiz, F. et al. A novel ultrasensitive assay for plasma p-tau217: Performance in individuals with subjective cognitive decline and early Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia 20, 1239\u20131249 (2024).","DOI":"10.1002\/alz.13525"},{"key":"54878_CR24","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.conb.2021.03.003","volume":"69","author":"S Wegmann","year":"2021","unstructured":"Wegmann, S., Biernat, J. & Mandelkow, E. A current view on Tau protein phosphorylation in Alzheimer\u2019s disease. Curr. Opin. Neurobiol. 69, 131\u2013138 (2021).","journal-title":"Curr. Opin. Neurobiol."},{"key":"54878_CR25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3389\/fnins.2018.00044","volume":"12","author":"T Kimura","year":"2018","unstructured":"Kimura, T., Sharma, G., Ishiguro, K. & Hisanaga, S. Phospho-Tau bar code: analysis of phosphoisotypes of Tau and its application to tauopathy. Front Neurosci. 12, 44 (2018).","journal-title":"Front Neurosci."},{"key":"54878_CR26","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/j.cell.2020.10.029","volume":"183","author":"H Wesseling","year":"2020","unstructured":"Wesseling, H. et al. Tau PTM profiles identify patient heterogeneity and stages of Alzheimer\u2019s disease. Cell 183, 1699\u20131713.e13 (2020).","journal-title":"Cell"},{"key":"54878_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnagi.2019.00121","volume":"11","author":"NR Barth\u00e9lemy","year":"2019","unstructured":"Barth\u00e9lemy, N. R., Mallipeddi, N., Moiseyev, P., Sato, C. & Bateman, R. J. Tau phosphorylation rates measured by mass spectrometry differ in the intracellular brain vs. Extracellular cerebrospinal fluid compartments and are differentially affected by Alzheimer\u2019s disease. Front. Aging Neurosci. 11, 1\u201318 (2019).","journal-title":"Front. Aging Neurosci."},{"key":"54878_CR28","doi-asserted-by":"publisher","first-page":"18213","DOI":"10.1074\/jbc.RA120.015882","volume":"295","author":"F Drepper","year":"2020","unstructured":"Drepper, F., Biernat, J., Kaniyappan, S. & Meyer, H. E. ARTICLE A combinatorial native MS and LC-MS \/ MS approach reveals high intrinsic phosphorylation of human Tau but minimal levels of other key modifications. J. Biol. Chem. 295, 18213\u201318225 (2020).","journal-title":"J. Biol. Chem."},{"key":"54878_CR29","doi-asserted-by":"crossref","unstructured":"Barth\u00e9lemy, N. R. et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease. 26, 398\u2013407 (2020).","DOI":"10.1038\/s41591-020-0781-z"},{"key":"54878_CR30","doi-asserted-by":"publisher","unstructured":"Wang, Z., Tan, L. & Yu, J. Axonal transport defects in Alzheimer\u2019 s disease. 1309\u20131321 https:\/\/doi.org\/10.1007\/s12035-014-8810-x (2015).","DOI":"10.1007\/s12035-014-8810-x"},{"key":"54878_CR31","doi-asserted-by":"publisher","unstructured":"Yu, L. et al. Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults. Acta Neuropathol. https:\/\/doi.org\/10.1007\/s00401-023-02570-4 (2023).","DOI":"10.1007\/s00401-023-02570-4"},{"key":"54878_CR32","doi-asserted-by":"publisher","first-page":"e1681","DOI":"10.1212\/WNL.0000000000012727","volume":"97","author":"A Leuzy","year":"2021","unstructured":"Leuzy, A. et al. Comparing the clinical utility and diagnostic performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. Neurology 97, e1681\u2013e1694 (2021).","journal-title":"Neurology"},{"key":"54878_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39328-1","volume":"14","author":"N Kyalu Ngoie Zola","year":"2023","unstructured":"Kyalu Ngoie Zola, N. et al. Specific post-translational modifications of soluble tau protein distinguishes Alzheimer\u2019s disease and primary tauopathies. Nat. Commun. 14, 3706 (2023).","journal-title":"Nat. Commun."},{"key":"54878_CR34","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13024-024-00741-9","volume":"19","author":"J Lantero-Rodriguez","year":"2024","unstructured":"Lantero-Rodriguez, J. et al. Tau protein profiling in tauopathies: a human brain study. Mol. Neurodegener. 19, 54 (2024).","journal-title":"Mol. Neurodegener."},{"key":"54878_CR35","doi-asserted-by":"crossref","unstructured":"Cicognola, C. et al. Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer\u2019s disease. Acta Neuropathologica vol. 137, 279\u2013296 (2019).","DOI":"10.1007\/s00401-018-1948-2"},{"key":"54878_CR36","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.neuron.2018.02.015","volume":"97","author":"C Sato","year":"2018","unstructured":"Sato, C. et al. Tau kinetics in neurons and the human central nervous system. Neuron 97, 1284\u20131298.e7 (2018).","journal-title":"Neuron"},{"key":"54878_CR37","unstructured":"Brinkmalm, G. et al. Phosphorylations Correlate With Disease Specific Isoforms In Sarkosyl Insoluble Tau From Brain. in (Gothenburg, Sweden, 2023)."},{"key":"54878_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-020-01019-z","volume":"8","author":"K Horie","year":"2020","unstructured":"Horie, K. et al. Regional correlation of biochemical measures of amyloid and tau phosphorylation in the brain. Acta Neuropathologica Commun. 8, 149 (2020).","journal-title":"Acta Neuropathologica Commun."},{"key":"54878_CR39","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00401-018-1948-2","volume":"137","author":"C Cicognola","year":"2019","unstructured":"Cicognola, C. et al. Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer\u2019 s disease. Acta Neuropathologica 137, 279\u2013296 (2019).","journal-title":"Acta Neuropathologica"},{"key":"54878_CR40","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3233\/JAD-150859","volume":"51","author":"BN Dugger","year":"2016","unstructured":"Dugger, B. N. et al. The presence of select tau species in human peripheral tissues and their relation to Alzheimer\u2019s disease. J. Alzheimer\u2019s. Dis. 51, 345\u2013356 (2016).","journal-title":"J. Alzheimer\u2019s. Dis."},{"key":"54878_CR41","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jamaneurol.2023.0199","volume":"80","author":"S Janelidze","year":"2023","unstructured":"Janelidze, S., Barth\u00e9lemy, N. R., He, Y., Bateman, R. J. & Hansson, O. Mitigating the associations of kidney dysfunction with blood biomarkers of Alzheimer disease by using phosphorylated tau to total Tau ratios. JAMA Neurol. 80, 516\u2013522 (2023).","journal-title":"JAMA Neurol."},{"key":"54878_CR42","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari, T. K. et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 19, 422\u2013433 (2020).","journal-title":"Lancet Neurol."},{"key":"54878_CR43","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nbt.1641","volume":"28","author":"DM Rissin","year":"2010","unstructured":"Rissin, D. M. et al. Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat. Biotechnol. 28, 595\u2013599 (2010).","journal-title":"Nat. Biotechnol."},{"key":"54878_CR44","doi-asserted-by":"publisher","first-page":"100629","DOI":"10.1016\/j.mcpro.2023.100629","volume":"22","author":"CE Teunissen","year":"2023","unstructured":"Teunissen, C. E. et al. Methods to discover and validate biofluid-based biomarkers in neurodegenerative dementias. Mol. Cell. Proteom. 22, 100629 (2023).","journal-title":"Mol. Cell. Proteom."},{"key":"54878_CR45","unstructured":"Vanmechelen, E. & Vanderstichele, H. Diagnosis Of Tauopathies Determining Tau\/phospho-tau Ratio. (2002)."},{"key":"54878_CR46","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/alz.12841","volume":"19","author":"NJ Ashton","year":"2023","unstructured":"Ashton, N. J. et al. Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays. Alzheimers Dement 19, 1913\u20131924 (2023).","journal-title":"Alzheimers Dement"},{"key":"54878_CR47","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack, C. R. et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s. Dement. 14, 535\u2013562 (2018).","journal-title":"Alzheimer\u2019s. Dement."},{"key":"54878_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fnins.2021.647783","volume":"15","author":"G Bellomo","year":"2021","unstructured":"Bellomo, G. et al. Machine learning driven profiling of cerebrospinal fluid core biomarkers in Alzheimer\u2019s disease and other neurological disorders. Front. Neurosci. 15, 1\u20139 (2021).","journal-title":"Front. Neurosci."},{"key":"54878_CR49","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1093\/brain\/awr179","volume":"134","author":"K Rascovsky","year":"2011","unstructured":"Rascovsky, K. et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 134, 2456\u20132477 (2011).","journal-title":"Brain"},{"key":"54878_CR50","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1212\/WNL.0b013e31821103e6","volume":"76","author":"ML Gorno-Tempini","year":"2011","unstructured":"Gorno-Tempini, M. L. et al. Classification of primary progressive aphasia and its variants. Neurology 76, 1006\u20131014 (2011).","journal-title":"Neurology"},{"key":"54878_CR51","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181c47cc2","volume":"73","author":"CE Teunissen","year":"2009","unstructured":"Teunissen, C. E. et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73, 1914\u20131922 (2009).","journal-title":"Neurology"},{"key":"54878_CR52","first-page":"291","volume":"11","author":"M R\u00f3zga","year":"2019","unstructured":"R\u00f3zga, M., Bittner, T., Batrla, R. & Karl, J. Preanalytical sample handling recommendations for Alzheimer\u2019s disease plasma biomarkers. Alzheimer\u2019s. Dement.: Diagnosis, Assess. Dis. Monit. 11, 291\u2013300 (2019).","journal-title":"Alzheimer\u2019s. Dement.: Diagnosis, Assess. Dis. Monit."},{"key":"54878_CR53","unstructured":"R Core Team (2019). R: A Language And Environment For Statistical Computing. (R Foundation for Statistical Computing, Vienna, Austria, 2019)."},{"key":"54878_CR54","unstructured":"Cohen, J. et al. Statistical Power Analysis for the Behavioral Sciences. (Routledge, New York, 1988)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54878-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54878-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54878-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T17:03:28Z","timestamp":1735923808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54878-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["54878"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-54878-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"12 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ALW completed the experiments during the internship at Quanterix Corp. that was an integral part of MIRIADE project (European Union\u2019s Horizon 2020 research and innovation program under grant agreement no. 860197). GB received honoraria from Fujirebio and completed paid consultancies for Parkinson\u2019s Foundation. He received travel\/educational grants from Fujirebio and Alzheimer\u2019s Association. LG has participated in advisory boards for, and received writing or speaker honoraria and travel grants from, Almirall, Biogen, Eisai, Euroimmun, Fujirebio, Lilly, Merck, Mylan, Novartis, Roche, Sanofi, Siemens Healthineers, and Teva. LP served as Member of Advisory Boards for Fujirebio, IBL, Roche, and Merck. CET is employed by Amsterdam UMC. She has grants or contracts for Research of the European Commission (Marie Curie International Training Network, grant agreement No. 860197 (MIRIADE), Innovative Medicines Initiatives 3TR (Horizon 2020, grant no 831434) EPND (IMI 2 Joint Undertaking (JU), grant no. 101034344) and JPND (bPRIDE), National MS Society (Progressive MS alliance), Alzheimer Drug Discovery Foundation, Alzheimer Association, Health Holland, the Dutch Research Council (ZonMW), including TAP-dementia, a ZonMw funded project (#10510032120003) in the context of the Dutch National Dementia Strategy, Alzheimer Drug Discovery Foundation, The Selfridges Group Foundation, Alzheimer Netherlands. She is recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). She is also a contract researcher for ADx Neurosciences, AC-Immune, Aribio, Axon Neurosciences, Beckman-Coulter, BioConnect, Bioorchestra, Brainstorm Therapeutics, Celgene, Cognition Therapeutics, EIP Pharma, Eisai, Eli Lilly Fujirebio, Grifols, Instant Nano Biosensors, Merck, Novo Nordisk, Olink, PeopleBio, Quanterix, Roche, Siemens, Toyama, Vivoryon, and the European Commission. She has received payment or honoraria from Roche, Novo Nordisk, and Grifols, where all payments were made to her institution. She also serves on editorial boards of Medidact Neurologie\/Springer; and in Neurology: Neuroimmunology & Neuroinflammation. She is editor of Alzheimer Research and Therapy. DC received travel\/educational grant from Fujirebio.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"214"}}